| risperidone / Generic mfg. |
ACTRN12619001569190: Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Risperidone Extended Release Capsules in Patients with Schizophrenia, Schizoaffective Disorder or Bipolar 1 Disorder |
|
|
| Not yet recruiting | 1 | 8 | | | Lyndra Australia Pty Ltd, Lyndra Australia Pty Ltd | Schizophrenia, Schizoaffective disorder, Bipolar 1 disorder | | | | |
NCT00986336: A Pharmacokinetic Study of Risperidone and Topiramate Administered Alone and in Combination in Patients With Bipolar Disorder or Schizoaffective Disorders |
|
|
| Completed | 1 | 56 | US | topiramate, risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Bipolar Disorder | | 11/02 | | |
NCT00791232: A Study of Extended Release Extended-release (ER) OROS Paliperidone Tolerability, as Compared to Immediate-release (IR)Risperidone, in Patients With Schizophrenia |
|
|
| Completed | 1 | 113 | US | extended-release (ER) OROS paliperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia | | 06/03 | | |
NCT00645502: Bioequivalence Study Comparing 2 Formulations for 4 mg Risperidone Tablet. |
|
|
| Completed | 1 | 40 | US | risperidone | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Schizoaffective Disorders | | 07/03 | | |
NCT00796185: As Study of the Pharmacokinetics of Paliperidone Extended-release and Risperidone Immediate-release Formulations |
|
|
| Completed | 1 | 62 | US | Paliperidone ER | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Schizophrenia, Schizoaffective Disorder | | 01/04 | | |
NCT00147394: Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD) |
|
|
| Completed | 1 | 100 | US | Risperidone | Children's Hospital Medical Center, Cincinnati | Child Development Disorders, Pervasive | | 06/04 | | |
NCT00255879: Movement Disorders Caused by Antipsychotic Drugs in Older Patients |
|
|
| Completed | 1 | 250 | US | Quetiapine, Risperidone, Olanzapine | University of California, San Diego, National Institute of Mental Health (NIMH) | Dyskinesia, Drug-Induced | 08/04 | 08/04 | | |
NCT00364429: SPECT Investigation Of The NMDA Receptor System In Healthy Volunteers And Patients With Schizophrenia |
|
|
| Terminated | 1 | 55 | Europe | [123]I-CNS 1261, Lorazepam, Risperidone | GlaxoSmithKline | Schizophrenia | 07/05 | 07/05 | | |
NCT00269035: SPECT Study With SB-773812 In Schizophrenic Patients |
|
|
| Completed | 1 | 95 | Europe | SB773812, Risperidone | GlaxoSmithKline | Schizophrenia | 05/07 | 05/07 | | |
NCT00500201: A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets. |
|
|
| Completed | 1 | 18 | Europe | SB- 773812 60 mg, SB- 773812, SB- 773812 120 mg, Placebo | GlaxoSmithKline | Schizophrenia | 07/07 | 07/07 | | |
NCT00411866: Effects Of The Drug Ketoconazole On How The Body Handles The Drug SB773812 |
|
|
| Completed | 1 | 36 | Europe | SB773812, Ketoconazole | GlaxoSmithKline | Schizophrenia | 10/07 | 10/07 | | |
NCT03730857: Early Predictors of Poor Treatment Response in Patients With Schizophrenia Treated With Atypical Antipsychotics |
|
|
| Completed | 1 | 111 | NA | Olanzapine, second-generation antipsychotics, risperidone, Paliperidone, second-generationantipsychotics | Calo Psychiatric Center | Schizophrenia | 12/08 | 12/08 | | |
NCT00466310: Metabolic Signatures and Biomarkers in Schizophrenia |
|
|
| Completed | 1 | 71 | US | Aripiprazole, Abilify, Risperidone, Risperdal, Healthy volunteers | Duke University, Bristol-Myers Squibb | Schizophrenia | 01/09 | 01/11 | | |
| Completed | 1 | 60 | US | SB773812 | GlaxoSmithKline | Schizophrenia | | | | |
NCT00821600: Characterization of Intramuscular Injections of Risperidone 4 Week Long-acting Injectable (LAI) Formulation in the Buttock of Patients With Schizophrenia |
|
|
| Completed | 1 | 24 | US | risperidone IR and LAI formulation | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Psychotic Disorders, Schizophrenia | 06/09 | 06/09 | | |
APSEP, NCT01259973: Typical Versus Atypical Antipsychotics; Occupation of Striatal Receptors and the Appearance of Extrapyramidal Symptomatology, in Healthy Volunteers |
|
|
| Unknown status | 1 | 24 | Europe | Risperidone, Placebo, Haloperidol | Hospital Clinic of Barcelona, Fundacion Clinic per a la Recerca Biomédica, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau, University of Barcelona | Pharmacogenetics, Healthy | 11/11 | 12/11 | | |
NCT01376076: Effects of Cariprazine on Cardiac Repolarization in Patients With Schizophrenia |
|
|
| Completed | 1 | 129 | US | Cariprazine, Risperidone/Moxifloxacin | Forest Laboratories | Schizophrenia | 02/12 | 02/12 | | |
NCT01607762: A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics |
|
|
| Completed | 1 | 31 | Europe | Aripiprazole, Quetiapine, Olanzapine, Risperidone, Paliperidone | Janssen Research & Development, LLC | Healthy | 04/12 | 10/12 | | |
NCT02019329: A Study of the Safety, Tolerability and Pharmacokientics of RO5545965 in Patients With Schizophrenia on Risperidone |
|
|
| Completed | 1 | 32 | US | Placebo, RO5545965, risperidone | Hoffmann-La Roche | Schizophrenia | 08/14 | 08/14 | | |
NCT02087579: Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants |
|
|
| Completed | 1 | 305 | US, Europe, RoW | Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, INVEGA®, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, RISPERDAL®, Risperidone, LAI | Janssen Research & Development, LLC | Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder | 10/14 | 12/14 | | |
ChiCTR-IPR-15006764: Comparative bioavailability of dispersible and conventional tablets of risperidone: a randomized, open-label, two-period crossover study in healthy male Chinese volunteers |
|
|
| Not yet recruiting | 1 | 48 | | The volunteers was given 1 mg*2 Risperidone dispersible tablets in first cycle, and 1 mg*2 Risperidone tablets in second cycle. ;The volunteers was given 1 mg*2 Risperidone tablets in first cycle , and 1 mg*2 Risperidone dispersible tablets in second cycle. ;The volunteers was given 1 mg*2 Risperidone dispersible tablets after breakfast in first cycle , and 1 mg*2 Risperidone tablets after breakfast in second cycle. ;The volunteers was given 1 mg*2 Risperidone tablets after breakfast in first cycle , and 1 mg*2 Risperidone dispersible tablets after breakfast in second cycle. | The first affiliated hospital, School of Medicine, Zhejiang University; Level of the institution：, Wanbangde Pharmaceutical Group Co., Ltd | schizophrenia | | | | |
NCT02634463: Whole Blood and Plasma Sample Collection for the Development of Antipsychotic Immunoassays From Participants Taking Aripiprazole, Olanzapine, Paliperidone, or Risperidone |
|
|
| Completed | 1 | 81 | Europe | Aripiprazole, Olanzapine, Paliperidone, Risperidone | Janssen Research & Development, LLC | Immunoassay, Antipsychotic | 11/16 | 11/16 | | |
CBD-IS, NCT02051387: Cannabidiol as a Different Type of an Antipsychotic: Drug Delivery and Interaction Study |
|
|
| Completed | 1 | 74 | Europe | Cannabidiol CR, Arvisol, Cannabidiol, Amisulpride, Olanzapine, Quetiapine, Risperidone, Placebo | Central Institute of Mental Health, Mannheim, University of Cologne | Schizophrenia | 08/17 | 08/17 | | |
NCT04587115: Reducing the Abuse Liability of Prescription Opioids |
|
|
| Completed | 1 | 15 | US | Risperidone, Risperdal, Ziprasidone, Geodon, Oxycodone, Oxycontin | The University of Texas Health Science Center at San Antonio | Addiction | 06/19 | 01/20 | | |
ChiCTR1900024422: The mutual promotion between family intervention and rTMS therapy improve cognitive function and negative symptoms in patients with schizophrenia |
|
|
| Recruiting | 1 | 400 | | Risperidone ;Risperidone+rTMS ;Risperidone+rTMS+family intervention ;Risperidone+family intervention | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, National Natural Science Foundation of China | schizophrenia | | | | |
NCT03790085: Identification of Multi-modal Bio-markers for Early Diagnosis and Treatment Prediction in Schizophrenia Individuals |
|
|
| Unknown status | 1 | 2700 | RoW | Risperidone, Olanzapine, Aripiprazole | Tianjin Medical University General Hospital, Shanghai Mental Health Center, Nanjing Medical University, Tianjin Anding Hospital, Harbin First Specialist Hospital, First Affiliated Hospital of Chongqing Medical University, Anhui Mental Health Center, Wuhan Psychiatric Hospital, Wenzhou Seventh People's Hospital, First Affiliated Hospital of Harbin Medical University | Schizophrenia, Major Depressive Disorder, Anxiety Disorders | 06/20 | 12/20 | | |
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard |
|
|
| Completed | 1 | 31 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Sumitomo Pharma America, Inc. | Schizophrenia | 09/23 | 09/23 | | |
QUARTZ, NCT06276361: Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia |
|
|
| Recruiting | 1 | 100 | RoW | Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Deltoids | Rovi Pharmaceuticals Laboratories | Schizophrenia | 05/26 | 05/26 | | |
NCT05542264: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia |
|
|
| Completed | 1 | 19 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Sumitomo Pharma America, Inc. | Schizophrenia | 02/24 | 02/24 | | |
| Recruiting | 1 | 12 | Europe | Risperidone oral solution, Twinings English Breakfast tea, Pepsi Max beverage | Helsinki University Central Hospital, University of Helsinki | Psychosis, Food-drug Interaction | 12/24 | 12/24 | | |
